Jubilant Pharmova Limited has notified shareholders of an August 14, 2026, deadline to submit tax documentation for its proposed final dividend of ₹5 per equity share. The communication, issued on August 1, 2026, outlines withholding tax rates and exemption procedures under the Income-tax Act, 2025, ensuring investors can optimize their tax liability before the record date of July 24, 2026. This procedural update follows the Board’s recommendation of the dividend on May 22, 2026, subject to approval at the Annual General Meeting (AGM) scheduled for August 26, 2026.

Dividend Taxation and Submission Deadlines

The company will deduct tax at source (TDS) based on shareholder category and residential status unless valid exemptions are claimed. Shareholders must submit requisite forms and declarations to Alankit Assignments Limited or their Depository Participants by August 14, 2026. Documents received after this date will not be considered for lower or nil tax deduction.

For resident individuals, no tax will be deducted if the total dividend received in FY 2026-27 does not exceed ₹10,000. However, if PAN is not registered or linked with Aadhaar, TDS will be applied at a higher rate of 20% under Section 397(2) of the Income-tax Act, 2025, regardless of the dividend amount. Non-resident shareholders seeking treaty benefits must provide a Tax Residency Certificate, e-filed Form 41, and a self-declaration confirming no permanent establishment in India.

AGM and Financial Context

The dividend recommendation is part of the business transacted at the 48th AGM on August 26, 2026. The meeting will also adopt audited financial statements for FY 2025-26, where Jubilant Pharmova reported revenue from operations of ₹82,796 million, a 14% increase year-on-year. Normalised Profit After Tax (PAT) rose 7% to ₹4,424 million. The proposed dividend aggregates to ₹796.41 million.

Shareholders holding shares in dematerialized mode are advised to update KYC details, including PAN and bank accounts, with their Depository Participants. Those holding physical shares must coordinate directly with the company or its Registrar and Transfer Agent. The company reserves the right to verify PAN status independently and apply higher withholding rates if discrepancies are found.

Key Dates for Shareholders

Investors are urged to consult tax advisors as the communication does not constitute exhaustive tax advice. The company will issue TDS certificates via email post-filing of returns, allowing shareholders to download Form 168 from the Income Tax Department’s portal.

Jubilant Pharmova Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY26 to the National Stock Exchange of India Limited and BSE Limited on August 1, 2026, disclosing robust environmental, social, and governance (ESG) performance metrics. The filing, mandated under Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, underscores the company’s commitment to sustainable practices, highlighted by an NSE Sustainability score of 72/100 placing it in the ‘Leader’ category and a Crisil ESG rating of 63/100.

The report was signed by Naresh Kapoor, Company Secretary, and covers consolidated disclosures for Jubilant Pharmova Limited and its subsidiaries. TUV SUD South Asia Pvt. Ltd. provided reasonable assurance for the BRSR Core attributes, verifying the accuracy of key sustainability indicators. The filing details the company’s progress against specific sustainability goals set for FY26, including targets for energy efficiency, waste management, and employee well-being.

Environmental Performance and Targets

Jubilant Pharmova reported significant achievements in its environmental sustainability goals for FY26. The company exceeded its target for renewable energy usage, achieving 41.6% of total purchased power from renewable sources against a target of 25.62%. Specific greenhouse gas (GHG) emissions were reduced to 7.86 tCO2e/Cr. INR, surpassing the target of 11.69 tCO2e/Cr. INR. Additionally, specific water consumption decreased to 70.9 m3/Cr. INR, well below the target of 88.75 m3/Cr. INR.

The company implemented three new energy-saving projects in its Indian operations during FY26, contributing to a reduction of 1,378.5 tCO2 in GHG emissions. Total Scope 1 and Scope 2 emissions intensity stood at 0.79 gmCO2e/INR, down from 1.03 gmCO2e/INR in FY25. All Indian manufacturing sites operate as Zero Liquid Discharge (ZLD) facilities, complying with local regulatory requirements.

Social Metrics and Employee Well-being

On the social front, Jubilant Pharmova maintained a workforce of 3,786 employees and 2,600 workers at the end of FY26. Women constituted 26% of the total employee count and 18% of the worker count. The company reported a turnover rate of 18% for permanent employees and 10% for permanent workers in FY26, compared to 22% and 11% respectively in FY25.

Employee training initiatives saw increased engagement, with 9.7 training man-days per employee per year achieved against a target of 6.7. The company reported two complaints related to sexual harassment under the POSH Act in FY26, both of which were resolved, with zero complaints upheld. Gross wages paid to females accounted for 12.7% of total wages paid, up from 9.7% in FY25.

Governance and Stakeholder Engagement

Jubilant Pharmova’s Board of Directors oversees sustainability through the CSR & Sustainability Committee, which reviews performance bi-annually. The company adheres to international standards including ISO 14001, ISO 9001, ISO 27001, and ISO 45001 across its facilities. In terms of stakeholder engagement, the company received 802 customer complaints regarding delivery of essential services in FY26, with 71 pending resolution at year-end. No penalties or fines were reported from regulatory authorities during the period.

What the Numbers Show

The divergence between revenue stability and improved efficiency metrics indicates successful operational optimization. While the report notes stable revenues due to business diversification, the significant reduction in specific GHG emissions (from a target of 11.69 to an actual of 7.86 tCO2e/Cr. INR) and water consumption suggests that growth is not coming at the cost of increased resource intensity. This decoupling of operational scale from environmental impact is a critical indicator of mature sustainability practices in the pharmaceutical manufacturing sector.